Abstract
Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways. It has been shown to prolong survival in patients with metastatic colorectal cancer. Cutaneous toxicity is relatively common because of the inhibition of EGFR of normal epidermal cells. We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy. His findings resolved within weeks of the discontinuation of the drug. Cicatricial ectropion is a potential sequela of EGFR inhibition by cetuximab and can resolve without surgical intervention with the discontinuation of this drug.
| Language | English (US) |
|---|---|
| Pages | 62-63 |
| Number of pages | 2 |
| Journal | Ophthalmic Plastic and Reconstructive Surgery |
| Volume | 23 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2007 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
- Surgery
Cite this
Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. / Garibaldi, Daniel C.; Adler, Richard A.
In: Ophthalmic Plastic and Reconstructive Surgery, Vol. 23, No. 1, 01.2007, p. 62-63.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab
AU - Garibaldi,Daniel C.
AU - Adler,Richard A.
PY - 2007/1
Y1 - 2007/1
N2 - Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways. It has been shown to prolong survival in patients with metastatic colorectal cancer. Cutaneous toxicity is relatively common because of the inhibition of EGFR of normal epidermal cells. We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy. His findings resolved within weeks of the discontinuation of the drug. Cicatricial ectropion is a potential sequela of EGFR inhibition by cetuximab and can resolve without surgical intervention with the discontinuation of this drug.
AB - Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways. It has been shown to prolong survival in patients with metastatic colorectal cancer. Cutaneous toxicity is relatively common because of the inhibition of EGFR of normal epidermal cells. We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy. His findings resolved within weeks of the discontinuation of the drug. Cicatricial ectropion is a potential sequela of EGFR inhibition by cetuximab and can resolve without surgical intervention with the discontinuation of this drug.
UR - http://www.scopus.com/inward/record.url?scp=33846459000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846459000&partnerID=8YFLogxK
U2 - 10.1097/IOP.0b013e31802d9025
DO - 10.1097/IOP.0b013e31802d9025
M3 - Article
VL - 23
SP - 62
EP - 63
JO - Ophthalmic Plastic and Reconstructive Surgery
T2 - Ophthalmic Plastic and Reconstructive Surgery
JF - Ophthalmic Plastic and Reconstructive Surgery
SN - 0740-9303
IS - 1
ER -